{"disease":{"id":"neovascular-wet-age-related-macular-degeneration","name":"neovascular wet age related macular degeneration"},"drugs":{"marketed":[{"drug_id":"ranibizumab-eqrn","indication_name":"Neovascular (Wet) Age-Related Macular Degeneration (AMD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04847895","title":"Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications","phase":"","overall_status":"COMPLETED","enrollment_count":5500,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06184360","title":"Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)","phase":"","overall_status":"COMPLETED","enrollment_count":2079,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04270747","title":"A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":576,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05439629","title":"Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":488,"lead_sponsor_name":"Bio-Thera Solutions","has_results":false},{"nct_id":"NCT01972789","title":"Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":349,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04857177","title":"A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":312,"lead_sponsor_name":"Chong Kun Dang Pharmaceutical","has_results":false},{"nct_id":"NCT06717139","title":"Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":220,"lead_sponsor_name":"St. Erik Eye Hospital","has_results":false},{"nct_id":"NCT07484074","title":"A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"Ollin Biosciences, Inc.","has_results":false},{"nct_id":"NCT04126317","title":"Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT07390253","title":"Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Vienna Institute for Research in Ocular Surgery","has_results":false},{"nct_id":"NCT07501052","title":"Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Sam Chun Dang Pharm. Co. Ltd.","has_results":false},{"nct_id":"NCT05903794","title":"A Study of EXG102-031 in Patients With wAMD (Everest)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Exegenesis Bio","has_results":false},{"nct_id":"NCT05473715","title":"A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Bayer","has_results":true}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}